Uncategorized

FED funds combination therapy preclinical trials at AGADA

By January 21, 2015 No Comments

The Foundation to Eradicate Duchenne (FED) is supporting AGADA Biosciences in conducting combination therapy preclinical trials in DBA/mdx mice. FED has helped fund over $70 million in muscular dystrophy research. The results of these studies will show how multi-drug instead of single drug therapies can ameliorate muscular dystrophy pathology using innovative pharmocodynamic biomarker panels.